TABLE 2.

Clinical and laboratory outcomes of pre- and post- moxibustion in PDM group.

	PDM-pre	PDM-post	Z	P
Pain intensity measured by VAS	6.90 (6.40, 7.35)	2.90 (2.15, 3.40)	–4.016	< 0.001
Menstrual symptom intensity scores measured by CMSS	19.00 (13.50, 26.50)	5.00 (3.00, 8.00)	–4.019	< 0.001
Menstrual symptom duration scores measured by CMSS (days)	29.00 (18.00, 35.00)	6.00 (3.00, 7.50)	–4.016	< 0.001
PGF2α	689.46 (656.31, 784.05)	295.19 (247.17, 362.23)	–3.724	< 0.001
OT	155.84 (146.23, 162.89)	74.52 (49.16, 84.08)	–3.724	<0.001

Data was given as Q₅₀ (Q₂₅, Q₇₅).

Data of 21 PDM patients pre- and post- moxibustion was analyzed in pain intensity measured by VAS, menstrual symptom intensity scores measured by CMSS, and menstrual symptom duration scores measured by CMSS.

Data of 18 PDM patients pre- and post- moxibustion was analyzed in PGF_2α and OT.